Novel benzimidazole derivatives as expected anticancer agents

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Benzimidazole derivatives are known for diverse biological activities.
• Chalcones and related heterocyclic compounds are scaffolds for drug discovery.
• Developing novel anticancer agents is a critical area of research.

Purpose of the Study:

• To synthesize a new series of benzimidazole-based chalcones and their heterocyclic derivatives.
• To evaluate the in vitro anticancer activity of the synthesized compounds against human liver carcinoma (HEPG2) and rat adrenal medulla (PC12) cell lines.
• To identify potent anticancer lead compounds for further investigation.

Main Methods:

• Synthesis of 1-(1H-benzimidazol-2-yl)-3-(substituted)-2-propen-1-one analogues and related compounds.
• Cyclization reactions using various reagents to form pyridones, pyrimidinethiones, isoxazoles, aminopyrimidines, pyrazolines, and epoxy derivatives.
• Evaluation of anticancer activity using in vitro assays against HEPG2 and PC12 cell lines.

Main Results:

• A library of novel benzimidazole derivatives, including chalcones, isoxazoles, and pyrazolines, were successfully synthesized.
• Benzimidazole-2-isoxazole derivative 5a demonstrated significant anticancer potency against both HEPG2 and PC12 cells.
• Several benzimidazole chalcones (2c,e), mercaptoacetohydrazide (14), and thiosemicarbazide (15a,b) derivatives exhibited high potency against PC12 cells.

Conclusions:

• The synthesized benzimidazole derivatives represent a promising class of anticancer agents.
• Compound 5a is a potential lead candidate for the development of novel therapeutics against liver carcinoma and neuroendocrine tumors.
• Further structure-activity relationship studies are warranted to optimize the anticancer efficacy of these compounds.